684 related articles for article (PubMed ID: 26254083)
1. An Increased Serum N-Terminal Telopeptide of Type I Collagen, a Biochemical Marker of Increased Bone Resorption, Is Associated with Infliximab Therapy in Patients with Crohn's Disease.
Sugimoto K; Ikeya K; Iida T; Kawasaki S; Arai O; Umehara K; Watanabe F; Tani S; Oishi S; Osawa S; Yamamoto T; Hanai H
Dig Dis Sci; 2016 Jan; 61(1):99-106. PubMed ID: 26254083
[TBL] [Abstract][Full Text] [Related]
2. A 1-year prospective study of the effect of infliximab on bone metabolism in inflammatory bowel disease patients.
Veerappan SG; Healy M; Walsh B; O'Morain CA; Daly JS; Ryan BM
Eur J Gastroenterol Hepatol; 2016 Nov; 28(11):1335-44. PubMed ID: 27508327
[TBL] [Abstract][Full Text] [Related]
3. Altered bone metabolism in inflammatory bowel disease: there is a difference between Crohn's disease and ulcerative colitis.
Ardizzone S; Bollani S; Bettica P; Bevilacqua M; Molteni P; Bianchi Porro G
J Intern Med; 2000 Jan; 247(1):63-70. PubMed ID: 10672132
[TBL] [Abstract][Full Text] [Related]
4. Increased urinary N-telopeptide cross-linked type 1 collagen predicts bone loss in patients with inflammatory bowel disease.
Dresner-Pollak R; Karmeli F; Eliakim R; Ackerman Z; Rachmilewitz D
Am J Gastroenterol; 2000 Mar; 95(3):699-704. PubMed ID: 10710060
[TBL] [Abstract][Full Text] [Related]
5. Serum N-terminal telopeptide of type I collagen as a biomarker for predicting bone density loss in patients with Crohn disease.
Ishida N; Higuchi T; Miyazu T; Tamura S; Suzuki S; Tani S; Yamade M; Iwaizumi M; Hamaya Y; Osawa S; Furuta T; Sugimoto K
PLoS One; 2021; 16(4):e0250658. PubMed ID: 33905438
[TBL] [Abstract][Full Text] [Related]
6. Treatment with infliximab is associated with increased markers of bone formation in patients with Crohn's disease.
Abreu MT; Geller JL; Vasiliauskas EA; Kam LY; Vora P; Martyak LA; Yang H; Hu B; Lin YC; Keenan G; Price J; Landers CJ; Adams JS; Targan SR
J Clin Gastroenterol; 2006 Jan; 40(1):55-63. PubMed ID: 16340635
[TBL] [Abstract][Full Text] [Related]
7. Femoral neck osteopenia in patients with inflammatory bowel disease.
Pollak RD; Karmeli F; Eliakim R; Ackerman Z; Tabb K; Rachmilewitz D
Am J Gastroenterol; 1998 Sep; 93(9):1483-90. PubMed ID: 9732930
[TBL] [Abstract][Full Text] [Related]
8. Association of vitamin K deficiency with bone metabolism and clinical disease activity in inflammatory bowel disease.
Nakajima S; Iijima H; Egawa S; Shinzaki S; Kondo J; Inoue T; Hayashi Y; Ying J; Mukai A; Akasaka T; Nishida T; Kanto T; Tsujii M; Hayashi N
Nutrition; 2011 Oct; 27(10):1023-8. PubMed ID: 21482072
[TBL] [Abstract][Full Text] [Related]
9. Rapid improvement of bone metabolism after infliximab treatment in Crohn's disease.
Franchimont N; Putzeys V; Collette J; Vermeire S; Rutgeerts P; De Vos M; Van Gossum A; Franchimont D; Fiasse R; Pelckmans P; Malaise M; Belaiche J; Louis E
Aliment Pharmacol Ther; 2004 Sep; 20(6):607-14. PubMed ID: 15352908
[TBL] [Abstract][Full Text] [Related]
10. [Improvement of bone metabolism after infliximab therapy in Crohn's disease].
Miheller P; Muzes G; Zágoni T; Tóth M; Rácz K; Tulassay Z
Orv Hetil; 2005 Jul; 146(28):1477-80. PubMed ID: 16130441
[TBL] [Abstract][Full Text] [Related]
11. Altered levels of biochemical indices of bone turnover and bone-related vitamins in patients with Crohn's disease and ulcerative colitis.
Gilman J; Shanahan F; Cashman KD
Aliment Pharmacol Ther; 2006 Apr; 23(7):1007-16. PubMed ID: 16573803
[TBL] [Abstract][Full Text] [Related]
12. Vitamin D levels and bone metabolism in Chinese adult patients with inflammatory bowel disease.
Tan B; Li P; Lv H; Li Y; Wang O; Xing XP; Qian JM
J Dig Dis; 2014 Mar; 15(3):116-23. PubMed ID: 24354597
[TBL] [Abstract][Full Text] [Related]
13. Distinct Anti-IFI16 and Anti-GP2 Antibodies in Inflammatory Bowel Disease and Their Variation with Infliximab Therapy.
Caneparo V; Pastorelli L; Pisani LF; Bruni B; Prodam F; Boldorini R; Roggenbuck D; Vecchi M; Landolfo S; Gariglio M; De Andrea M
Inflamm Bowel Dis; 2016 Dec; 22(12):2977-2987. PubMed ID: 27636380
[TBL] [Abstract][Full Text] [Related]
14. The association of infliximab trough levels with disease activity in pediatric inflammatory bowel disease.
Hoekman DR; Brandse JF; de Meij TG; Hummel TZ; Löwenberg M; Benninga MA; D'Haens GR; Kindermann A
Scand J Gastroenterol; 2015; 50(9):1110-7. PubMed ID: 25865965
[TBL] [Abstract][Full Text] [Related]
15. Influence of polymorphisms and TNF and IL1β serum concentration on the infliximab response in Crohn's disease and ulcerative colitis.
Lacruz-Guzmán D; Torres-Moreno D; Pedrero F; Romero-Cara P; García-Tercero I; Trujillo-Santos J; Conesa-Zamora P
Eur J Clin Pharmacol; 2013 Mar; 69(3):431-8. PubMed ID: 22960943
[TBL] [Abstract][Full Text] [Related]
16. Correlation Between Anti-TNF Serum Levels and Endoscopic Inflammation in Inflammatory Bowel Disease Patients.
Chaparro M; Barreiro-de Acosta M; Echarri A; Almendros R; Barrio J; Llao J; Gomollón F; Vera M; Cabriada JL; Guardiola J; Guerra I; Beltrán B; Roncero O; Busquets D; Taxonera C; Calvet X; Ferreiro-Iglesias R; Ollero Pena V; Bernardo D; Donday MG; Garre A; Godino A; Díaz A; Gisbert JP
Dig Dis Sci; 2019 Mar; 64(3):846-854. PubMed ID: 30426297
[TBL] [Abstract][Full Text] [Related]
17. Reduced bone mineral density and unbalanced bone metabolism in patients with inflammatory bowel disease.
Schulte C; Dignass AU; Mann K; Goebell H
Inflamm Bowel Dis; 1998 Nov; 4(4):268-75. PubMed ID: 9836078
[TBL] [Abstract][Full Text] [Related]
18. Infliximab trough levels are decreasing over time in patients with inflammatory bowel disease on maintenance treatment with infliximab.
Orfanoudaki E; Gazouli M; Foteinogiannopoulou K; Theodoraki E; Legaki E; Romanos I; Mouzas I; Koutroubakis IE
Eur J Gastroenterol Hepatol; 2019 Feb; 31(2):187-191. PubMed ID: 30543573
[TBL] [Abstract][Full Text] [Related]
19. Bone mineral density in patients with inflammatory bowel disease: a population-based prospective two-year follow-up study.
Jahnsen J; Falch JA; Mowinckel P; Aadland E
Scand J Gastroenterol; 2004 Feb; 39(2):145-53. PubMed ID: 15000276
[TBL] [Abstract][Full Text] [Related]
20. Dosing interval and diagnosis predict infliximab levels in patients with inflammatory bowel disease on maintenance treatment.
Krajcovicova A; Batovsky M; Gregus M; Hlista M; Durina J; Leskova Z; Sturdik I; Gojdic M; Jalali Y; Koller T; Toth J; Huorka M; Hlavaty T
Acta Gastroenterol Belg; 2018; 81(4):465-470. PubMed ID: 30645913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
